Elmehdi Fraj

Dr. Elmehdi Fraj

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Plants
Verified
Journal Article
Open access
PDF file
HBhaytham bouammali
haytham bouammali
LZLinda Zraibi
Linda Zraibi
IZImane Ziani
Imane Ziani
DMDr Merzouki
Dr Merzouki
LBLamiae Bourassi
Lamiae Bourassi
Rachid TouzaniRachid Touzani
Rachid Touzani
Rosmarinus officinalis L. compounds, especially its main polyphenolic compounds, carnosic acid (CA) and rosmarinic acid (RA), influence various facets of cancer biology, making them valuable assets in the ongoing fight against cancer. These two secondary metabolites exhibit formidable antioxidant properties that are a pivotal contributor against the development of cancer. Their antitumor effect has been related to diverse mechanisms. In the case of CA, it has the capacity to induce cell death of cancer cells through the rise in ROS levels within the cells, the inhibition of protein kinase AKT, the activation of autophagy-related genes (ATG) and the disrupt mitochondrial membrane potential. Regarding RA, its antitumor actions encompass apoptosis induction through caspase activation, the inhibition of cell proliferation by interrupting cell cycle progression and epigenetic regulation, antioxidative stress-induced DNA damage, and interference with angiogenesis to curtail tumor growth. To understand the molecular interaction between rosemary compounds (CA and RA) and a protein that is involved in cancer and inflammation, S100A8, we have performed a series of molecular docking analyses using the available three-dimensional structures (PDBID: 1IRJ, 1MR8, and 4GGF). The ligands showed different binding intensities in the active sites with the protein target molecules, except for CA with the 1MR8 protein.

3 December 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HBhaytham bouammali
haytham bouammali
OKOussama Khibech
Oussama Khibech
EFElmehdi Fraj
Elmehdi Fraj
Amine ElbouzidiAmine Elbouzidi
Amine Elbouzidi
ABAyoub Bekkouch
Ayoub Bekkouch
Rachid TouzaniRachid Touzani
Rachid Touzani

Verified
Journal Article
Open access
PDF file
EFElmehdi Fraj
Elmehdi Fraj
Amine ElbouzidiAmine Elbouzidi
Amine Elbouzidi
HBhaytham bouammali
haytham bouammali
HJHanane JAOUANI
Hanane JAOUANI
CBChaymae Bourhou
Chaymae Bourhou
BBBoufelja BOUAMMALI
Boufelja BOUAMMALI
The development of new anti-inflammatory agents with improved safety and efficacy remains a major therapeutic challenge, particularly in light of the adverse effects associated with conventional nonsteroidal anti-inflammatory drugs. In this study, a series of new flavone derivatives were synthesized and evaluated for their inhibitory activities against Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2), and 5-Lipooxygenase (5-LOX) through combined in vitro and in silico approaches. Biological screening demonstrated that several derivatives exhibited moderate to strong inhibitory activity across the three enzymes, with IC50 values ranging from 35.67 ± 2.92 to 1137.44 ± 371.05µM. Among these, compounds 5a and 5b emerged as the most promising dual COX-2/5-LOX inhibitors, displaying potent activity toward both targets while maintaining limited COX-1 inhibition, as reflected by their favorable selectivity indices (SI = 2.09 and 5.21, respectively). Molecular docking studies supported the experimental findings, revealing favorable binding affinities of compounds 5a and 5b within the COX-2 active site (PDB: 1CX2), while the flavone–tetrazole hybrid 6b exhibited the highest binding affinity toward the 5-LOX active site (PDB: 6N2W), consistent with its notable inhibitory activity. In silico ADME and toxicity predictions further suggested that the selected derivatives (4a-b, 5a-b, and 6a-b) possess acceptable physiochemical properties, low predicted toxicity, and favorable drug-likeness. Overall, this study identifies flavone-based scaffolds as a promising early-stage lead for the development of dual COX-2/5-LOX inhibitors and provides a rational basis for the design of safer anti-inflammatory agents.